Human papillomavirus (HPV) infection significantly impacts women, as it can cause cancers and precancers of the cervix, vulva, vagina, oropharynx, and anus. However, many of these cancers can be prevented by HPV vaccination. Despite evidence of vaccine effectiveness and safety, vaccination rates remain low. Evidence-based strategies should be utilized to reduce barriers and increase vaccination rates.
Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. Approximately 85% of sexually active women and 91% of sexually active men will be infected with HPV in their lifetime [1]. Approximately half of new infections occur among individuals aged 15-24 years [2]. Though genital skin contact is the primary mode of transmission, the infection does not require sexual penetration [3]. The most common symptom of HPV infection is genital warts, although many infected people are asymptomatic, and the virus often resolves on its own. Physicians diagnosed over 400,000 cases of genital warts in 2013 [4]. However, the most serious consequence of HPV infection is cancer.HPV infection is known to cause cervical, vulvar, and vaginal cancer in women and penile cancer in men. It is also an attributable cause of anal and oropharyngeal cancer in both men and women. Between 1993 and 2005, HPV was linked to 90.6% of all cervical cancer cases, 70.1% of oropharyngeal cancers, and 91.1% of anal cancers in the United States [5].HPV-related cancers disproportionately affect women in the United States. There are 17,600 women affected by HPVrelated cancers annually; of those, approximately 11,000 are cervical cancer diagnoses [5]. In comparison, 9,300 men are affected by HPV-attributable cancer each year [5]. Women also have a higher prevalence of anal cancer than men (2,600 cases versus 1,400 cases annually). However, men have a higher prevalence of oropharyngeal cancer than women (7,200 cases versus 1,800 cases annually) [5]. Among women, the incidence of cervical cancer disproportionately affects African Americans and Latinas, who are more likely to be diagnosed with cervical cancer and have higher cervical cancer mortality rates than whites (see Table 1). Delayed diagnosis is a major contributor to this disparity [6]. White women have higher rates of HPV-associated anal and vulvar cancer than black and Latina women [6].The first HPV vaccine available in the United States, the quadrivalent HPV vaccine (4vHPV), was licensed in 2006 for females aged 9-26 years, although administration was routinely recommended at ages 11-12 years (prior to the onset of sexual activity for most adolescents) [7]. 4vHPV was approved for males permissively in 2009 for genital wart prevention and was recommended routinely for males in 2011, at which time 4vHPV was licensed by the US Food and Drug Administration for the prevention of anal cancer in both males and females [8]. The bivalent HPV vaccine (2vHPV) for cervical cancer prevention and the nonavalent HPV vaccine (9vHPV) were introduced in 2009 and 2014, respectivel...